Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sorrento Therpt (SRNE)

Sorrento Therpt (SRNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 453,005
  • Shares Outstanding, K 471,880
  • Annual Sales, $ 52,900 K
  • Annual Income, $ -428,330 K
  • 60-Month Beta 2.20
  • Price/Sales 5.98
  • Price/Cash Flow N/A
  • Price/Book 3.64
Trade SRNE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings -0.20 on 11/08/22
  • Next Earnings Date 02/14/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 152.49% ( -3.43%)
  • Historical Volatility 104.81%
  • IV Percentile 95%
  • IV Rank 42.52%
  • IV High 260.39% on 12/22/22
  • IV Low 72.68% on 08/03/22
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,790
  • Volume Avg (30-Day) 4,872
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 139,353
  • Open Int (30-Day) 228,256

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7400 +32.03%
on 12/28/22
1.2300 -20.57%
on 01/18/23
+0.2359 (+31.83%)
since 12/27/22
3-Month
0.7360 +32.74%
on 12/22/22
1.8900 -48.31%
on 11/11/22
-0.5530 (-36.14%)
since 10/27/22
52-Week
0.7360 +32.74%
on 12/22/22
3.6000 -72.86%
on 02/09/22
-1.9030 (-66.08%)
since 01/27/22

Most Recent Stories

More News
MarketBeat: Week in Review 01/09-01/13

Markets are looking for direction in early trading before a holiday weekend. Here are some of the popular stories MarketBeat analysts were covering this week.

SQ : 80.45 (-0.91%)
SNAP : 10.16 (-0.29%)
SHC : 16.67 (-0.77%)
SRNE : 0.9797 (+2.05%)
SCLX : 8.98 (+1.13%)
CWH : 24.29 (+0.21%)
M : 23.23 (-1.02%)
BABA : 119.65 (-0.76%)
WEN : 21.81 (-0.09%)
LMT : 456.36 (-0.75%)
BE : 24.74 (-0.12%)
AMZN : 99.51 (+0.29%)
Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move

Sorrento Therapeutics is on the move following preliminary results from its subsidiary Scilex. Scilex is making money with the company's 1st product to market

SRNE : 0.9797 (+2.05%)
SCLX : 8.98 (+1.13%)
Sorrento Therapeutics: Q3 Earnings Snapshot

Sorrento Therapeutics: Q3 Earnings Snapshot

SRNE : 0.9797 (+2.05%)
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ANIP : 43.53 (-0.16%)
SRNE : 0.9797 (+2.05%)
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

ATRA : 4.92 (-0.40%)
SRNE : 0.9797 (+2.05%)
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 231.59 (+1.12%)
SRNE : 0.9797 (+2.05%)
Why Sorrento Therapeutics Stock Is on the Rise Today

The drugmaker's stock is moving upward today in sympathy with the broader biopharmaceutical industry.

SRNE : 0.9797 (+2.05%)
Why Sorrento Therapeutics' Shares Tumbled 23.4% in September

Sorrento's financials are not helping it in the current down market.

SRNE : 0.9797 (+2.05%)
Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

MORF : 30.86 (-2.59%)
SRNE : 0.9797 (+2.05%)
3 Biotech Stocks Gaining Momentum

The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.

AMRN : 1.8800 (+3.87%)
SRNE : 0.9797 (+2.05%)
EDIT : 8.88 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and...

See More

Key Turning Points

3rd Resistance Point 1.0887
2nd Resistance Point 1.0543
1st Resistance Point 1.0072
Last Price 0.9770
1st Support Level 0.9257
2nd Support Level 0.8913
3rd Support Level 0.8442

See More

52-Week High 3.6000
Fibonacci 61.8% 2.5060
Fibonacci 50% 2.1680
Fibonacci 38.2% 1.8300
Last Price 0.9770
52-Week Low 0.7360

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar